62 related articles for article (PubMed ID: 22644862)
21. Tight junction modulation and its relationship to drug delivery.
Salama NN; Eddington ND; Fasano A
Adv Drug Deliv Rev; 2006 Apr; 58(1):15-28. PubMed ID: 16517003
[TBL] [Abstract][Full Text] [Related]
22. New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.
Nicoli S; Penna E; Padula C; Colombo P; Santi P
Int J Pharm; 2006 Nov; 325(1-2):2-7. PubMed ID: 16860952
[TBL] [Abstract][Full Text] [Related]
23. Recent progresses in bioadhesive microspheres via transmucosal administration.
Jiao Y; Pang X; Liu M; Zhang B; Li L; Zhai G
Colloids Surf B Biointerfaces; 2016 Apr; 140():361-372. PubMed ID: 26774569
[TBL] [Abstract][Full Text] [Related]
24. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.
Sudhakar Y; Kuotsu K; Bandyopadhyay AK
J Control Release; 2006 Aug; 114(1):15-40. PubMed ID: 16828915
[TBL] [Abstract][Full Text] [Related]
25. The effect of delta G on the transport and oral absorption of macromolecules.
Salama NN; Fasano A; Thakar M; Eddington ND
J Pharm Sci; 2004 May; 93(5):1310-9. PubMed ID: 15067707
[TBL] [Abstract][Full Text] [Related]
26. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
27. Permeation-enhancing effects of chitosan formulations on recombinant hirudin-2 by nasal delivery in vitro and in vivo.
Zhang YJ; Ma CH; Lu WL; Zhang X; Wang XL; Sun JN; Zhang Q
Acta Pharmacol Sin; 2005 Nov; 26(11):1402-8. PubMed ID: 16225765
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
[TBL] [Abstract][Full Text] [Related]
29. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.
Baboota S; Shakeel F; Ahuja A; Ali J; Shafiq S
Acta Pharm; 2007 Sep; 57(3):315-32. PubMed ID: 17878111
[TBL] [Abstract][Full Text] [Related]
30. In vivo stratum corneum distribution of lidocaine, assessed by tape stripping, from a new bioadhesive film.
Padula C; Fulgoni A; Santi P
Skin Res Technol; 2010 Feb; 16(1):125-30. PubMed ID: 20384891
[TBL] [Abstract][Full Text] [Related]
31. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
[TBL] [Abstract][Full Text] [Related]
32. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
33. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis.
Boirivant M; Amendola A; Butera A; Sanchez M; Xu L; Marinaro M; Kitani A; Di Giacinto C; Strober W; Fuss IJ
Gastroenterology; 2008 Nov; 135(5):1612-1623.e5. PubMed ID: 18765239
[TBL] [Abstract][Full Text] [Related]
34. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
35. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems.
Babu RJ; Pandit JK
Int J Pharm; 2005 Jan; 288(2):325-34. PubMed ID: 15620873
[TBL] [Abstract][Full Text] [Related]
36. Non-clinical safety evaluation of intranasal iota-carrageenan.
Hebar A; Koller C; Seifert JM; Chabicovsky M; Bodenteich A; Bernkop-Schnürch A; Grassauer A; Prieschl-Grassauer E
PLoS One; 2015; 10(4):e0122911. PubMed ID: 25875737
[TBL] [Abstract][Full Text] [Related]
37. Effect of Tight Junction-Modulating FCIGRL-Modified Peptides on the Intestinal Absorption of Doxorubicin in Rats.
Song KH
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794312
[TBL] [Abstract][Full Text] [Related]
38. A study of orally-administered degraded carrageenan in the baboon.
Beattie IA; Blakemore WR; Dewar ET; Warwick MH
Food Cosmet Toxicol; 1970 Jun; 8(3):257-66. PubMed ID: 4989219
[No Abstract] [Full Text] [Related]
39. Paracellular permeation-enhancing effect of AT1002 C-terminal amidation in nasal delivery.
Song KH; Kim SB; Shim CK; Chung SJ; Kim DD; Rhee SK; Choi GJ; Kim CH; Kim K
Drug Des Devel Ther; 2015; 9():1815-23. PubMed ID: 25848218
[TBL] [Abstract][Full Text] [Related]
40. The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.
Vanuytsel T; Vermeire S; Cleynen I
Tissue Barriers; 2013 Dec; 1(5):e27321. PubMed ID: 24868498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
